#diabetes #T2DM #antidiabeticagents #oraldiabeticagents FIGURE 9.1 Glucose-lowering medication in type 2 diabetes: overall approach. For appropriate context, see Figure 4.1. CREDENCE, Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy. CVOTs, CV outcomes trials; DPP-4i, dipeptidyl peptidase 4 inhibitor; GLP-1 RA, GLP-1 receptor agonist; SGLT2i, SGLT2 inhibitor; SU, sulfonylurea; TZD, thiazolidinedione. Adapted from Davies MJ, D’Alessio DA, Fradkin J, et al. Diabetes Care 2018;41:2669–2701 and Buse JB, Wexler DJ, Tsapas A, et al. Diabetes Care 19 December 2019 [Epub ahead of print]. DOI: 10.2337/dci19-0066

#BOVA #score #pulmonary #embolism #Risk #factors Basis underlying Bova score for PE complications/mortality. Factors associated with 30-day pulmonary embolism-related complications in 2216 normotensive patients with acute symptomatic pulmonary embolism. Stage I of the Bova Score should not be used to identify low-risk PE patients eligible for early discharge or outpatient therapy because it does not consider relevant comorbidities such as cancer or cardiopulmonary diseases. Citation: Bova C, Sanchez O, Prandoni P, Lankeit M, Konstantinides S, Vanni S, Jiménez D. Identification of intermediate-risk patients with acute symptomatic pulmonary embolism. Eur Respir J. 2014 Sep;44(3):694-703. doi: 10.1183/09031936.00006114. Epub 2014 Apr 2. PMID: 24696111.

#hyponatremia #coreIM